Victoria Sinclair

Biotech investor.
I love flowers, quiet mornings, and finding beauty in ordinary days.

[Victoria Sinclair @VicSinclair_]

Why Amylin Is Back in Obesity
Pramlintide was approved in 2005, but frequent injections limited its use. Now $LLY and $NVO are developing longer-acting amylin drugs and combinations that may complement GLP-1 through a different pathway.

[Victoria Sinclair @VicSinclair_]

@vipintukur Six clusters explains why one-size-fits-all trials may struggle here.

[Victoria Sinclair @VicSinclair_]

@exosome Aging really does find every system eventually.

[Victoria Sinclair @VicSinclair_]

@BrandonLuuMD Some relationships really do come with hidden fees.

[Victoria Sinclair @VicSinclair_]

@dantawfik Maybe immune aging isn’t just decline after all.

[Victoria Sinclair @VicSinclair_]

@bijans “For now” is doing a lot of work here.

[Victoria Sinclair @VicSinclair_]

@levie Life sciences might be one of the more interesting places to watch this play out.

[Victoria Sinclair @VicSinclair_]

@vintweeta Knowing more and knowing what matters aren’t always the same thing.

[Victoria Sinclair @VicSinclair_]

@NTFabiano Crazy how one experiment can open an entire field.

[Victoria Sinclair @VicSinclair_]

The mRNA Debate Is More Nuanced
$MRNA and $BNTX use modified nucleosides, while CureVac pursued sequence-optimized unmodified mRNA. Its first COVID vaccine delivered 48% efficacy, a setback, though delivery, dose and sequence design still shape each platform.

[Victoria Sinclair @VicSinclair_]

@SpecialSitsNews Healthcare showing up in more than one scenario is the interesting part for me.

[Victoria Sinclair @VicSinclair_]

@agingdoc1 Interesting biology. Still waiting on the clinical proof.

[Victoria Sinclair @VicSinclair_]

@illyquid Didn’t have monkeys on my biotech bottleneck bingo card.

[Victoria Sinclair @VicSinclair_]

@BoWang87 Now comes the fun part: turning those designs into drugs.

[Victoria Sinclair @VicSinclair_]

@QuanquanGu @Geodesiclab The wet lab is where this gets interesting.

[Victoria Sinclair @VicSinclair_]

@FredaDuan Phase II is still where the story gets real.

[Victoria Sinclair @VicSinclair_]

@HOThomasWPhelps One blockbuster apparently wasn’t enough.

[Victoria Sinclair @VicSinclair_]

@anthonystaj The revenue leap is doing a lot of work here.

[Victoria Sinclair @VicSinclair_]

@CMichaelGibson Need a bigger chart for EASD 2027🤣

[Victoria Sinclair @VicSinclair_]

@investseekers Maybe Novo finally gets a good earnings day 😆